Background: This systematic review was performed to investigate the effects of Chinese herbal nedicine (CHM) on cognitive function and activity of daily living (ADL) in individuals with Alzheimer's disease. Methods: Five electronic databases (Medline, Embase, Cinahl, PsycArticles, and CNKI) were searched from inception to January 2019. Randomized controlled trials (RCTs) assessing the effect of CHM on cognition and activity of daily living in adults with Alzheimer's disease were included. We pooled the effects size using the Comprehensive Meta-Analysis Software. Cochrane risk of bias tool was used to evaluate the study quality. 
Introduction
Alzheimer's disease (AD), as the most common form of dementia, is a neurodegenerative disorder, and it has multiple symptoms, such as cognitive impairment, activity limitation, depression, and even loss of independence in older adults. 1, 2 With the aggravated aging problem, a huge number of people are living with AD, which has represented a significant challenge for health issue around the world. 3 The World Alzheimer's Disease Report 2016 indicated that total 47 million populations were diagnosed dementia, and the estimated number will be increased to 131 million by 2050. 4 In today's United States, there are approximately 5.7 million adults who are suffering from the AD, and one of 10 people aged 65 years and over has AD according to the national statistic. 1 In South Korea, the Korea Ministry of Health and Welfare reported that Korean older people with dementia were about 0.5 million in 2012, and the predictable number is expected to increase to 2.7 million by 2050. 5 A variety of drugs for treatment AD have been applied to the clinic in the past decades. The conventional medicines are commonly aimed at declining the AD progression, such as increasing the level of acetylcholine (Donepezil, Galantamine, and Rivastigmine), and antagonist of the N-methyl-d-aspartate (NMDA) receptor by the Memantine. 3 However, a recent meta-analysis study revealed that the Memantine drug had smaller effects on dementia, 6 and some conventional medicines contributed to being small effects on cognitive function and ADL for people with AD in longterm treatment. 7, 8 Additionally, previous studies reported that cholinesterase inhibitors and the Memantine drug have different levels of side effects for patients with AD. 9, 10 Some patients even stopped taking these drugs.
Chinese herbal medicine (CHM) has been used to protect memory. 11 A growing body of evidence suggested that the improvements of cognitive function and ADL in patients with AD may be attributed to the CHM (multi-target intervention effects) to some extent. [12] [13] [14] [15] Some studies reported that CHM have similar effect on cognition and activity of daily living (ADL) improvement compared with conventional drug therapy. 16, 17 Although previous literature review studies [18] [19] [20] [21] showed several types of CHM may benefit their cognitive function, most of them included several types of dementia together (e.g., vascular dementia, Lewy body dementia) without quantitative analysis.
Therefore, the aim of this study was to investigate whether the CHM is more effective than the conventional drug therapies to improving cognitive and ADL deterioration for adults with AD.
Methods

Search strategy
Five electronic databases (Medline, Embase, Cinahl, PsycArticles, and CNKI) were searched for potential publications from their inception to January 2019. We used two groups of search terms to retrieve potentially relevant articles: (1) "Chinese herbal medicine" OR "Chinese herb" OR "traditional Chinese medicine" OR "Chinese medicine"; (2) "Alzheimer's disease" OR "Alzheimer*" OR "Senile Dementia". In addition, reference lists of initially retrieved documents were also screened to identify potential publications that were related to our interesting topic. If so, manual search was performed.
For example, the search strategy was conducted in Medline database:
#1: Chinese herbal medicine #2: Chinese herb #3: traditional Chinese medicine #4: Chinese medicine #5: #1 OR #2 OR #3 OR #4 #6: Alzheimer's disease #7: Alzheimer* #8: #6 OR #7 #9: #5 AND #8
Inclusion and exclusion criteria
The inclusion criteria were like following.
Participants
Participants diagnosed with AD according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) III, III-R or IV were taken into consideration, regardless of gender, age, duration of the disease. We excluded individuals diagnosed with other types of dementia (e.g., vascular dementia, Lewy body disease), or mild cognitive impairment. Fig. 1 . Flow diagram of the literature search process based on the PRISMA guideline. PRISMA, preferred reporting items for systematic reviews and meta-analyses; AD, Alzheimer's disease; MCI, mild cognitive impairment.
Interventions
CHM was defined as the prescription consisting of multiple herbs or patent herbal products. We excluded the combination of CHM with injections or acupuncture.
Control
We included conventional drug therapies (including donepezil, memantine, and galantamine), placebo or no intervention as control interventions.
Outcomes
The outcome measurements were Mini-Mental State Examination (MMSE) and ADL.
We excluded conference proceeding, case-study, crosssectional studies, controlled study with no randomization, or review.
Data extraction
The key information of all eligible studies were independently extracted by two reviewers; author and year of publication, characteristics of subjects, sample size, gender and age, study design, intervention protocol, outcome measurements, and statistical data (mean and standard deviation and the number of participants of each group) needed for computing effect size.
Risk of bias assessment
The risk of bias of all randomized controlled trials were evaluated according to the Cochrane risk of bias tool. 22 This scale involves 7-domain assessment: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias.
Statistical analysis
This meta-analysis was performed using the Comprehensive Meta-Analysis Software. As the cognition and ADL were measured by different scales across the eligible studies, we used the standardized mean difference (SMD) with random-effects model with 95% confidence interval (CI). Three levels of effect size (small [0.2-0.49], medium [0.5-0.79], and large [0.8 or more]) were taken as the corresponding magnitudes of intervention effect. The I 2 statistic was employed to assess heterogeneity, and it was classified as 25% (low heterogeneity), 50% (moderate heterogeneity), and 75% (high heterogeneity). 23 The Egger's regression test was used to examine the publication bias. In addition, subgroup meta-analysis was performed based on the type of CHM interventions.
Results
Search results
The search and selection process of this review was described based on the PRISMA guideline in Fig. 1 . 24 A total of 13,851 records were identified at the initial stage. After removing duplicates (n = 178), the titles and abstracts (n = 13,673) of remaining articles were screened by two independent reviewers to further determine the eligibility of potential articles; this led to elimination of 13,596 articles. Seventy-seven full-text articles were further assessed and 53 articles were excluded. Finally, 24 RCT articles regarding to the effects of CHM on cognitive function and ADL were included in this review. [14] [15] [16] [17] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] 
Study characteristics
Details of the included studies are shown in Tables 1 and 2 . The studies were published from 2001 to 2018. In total, 1711 participants (mean age from 60 to 84 years) with mild to severe degree of AD were included in this review along with sample size across studies ranging from 20 to 186.
The type of CHM treatment varied greatly across the included studies and its intervention duration lasted 2-to 6-month. In the control group where participants were treated with either Donepezil or Piracetam on cognitive function [14] [15] [16] [17] [25] [26] [27] [28] [29] [30] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] and ADL [15] [16] [17] 25, 27, [29] [30] [31] [32] [33] [34] [37] [38] [39] [40] [41] were the main outcome measures across the studies included.
Risk of bias assessment
Details of the quality assessment for each study are presented in Table 3 . In term of random sequence generation, the random number approach was presented in five studies, 26, 28, 31, 35 and 18 studies did not report clearly the random allocation strategies. [14] [15] [16] [17] 26, [28] [29] [30] [31] [32] [34] [35] [36] [37] [38] [39] 41, 44 Two studies were high risk of bias due to lack of the random sequence generation. 27, 33 In aspect of allocation concealment, one study reported the allocation concealment, 28 and 18 studies did not state the details of allocation concealment. [14] [15] [16] [17] [26] [27] [28] [29] [30] [32] [33] [34] [37] [38] [39] [40] [41] 44 The methods of blinding of participants and personnel were only reported in one study 16 the rest of studies were not described. For blinding of outcome assessment, 23 studies did not provide the detailed information, 14, 15, 17, 25, [27] [28] [29] [30] [31] [32] [33] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] and only one study were low risk of bias. 16 The incomplete outcome data was described in all studies. Finally, for the aspect of selective reporting and other bias, none studies reported the clear risk of bias.
Synthesized results
Cognitive function
A total of 23 studies 14, [25] [26] [27] [28] [29] [30] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] were to investigate the effect CHM versus conventional drug in term of cognitive function, measured by MMSE. The pooled results from 23 studies indicated that CHM had significant effect on cognition (SMD = 0.66, 95% CI [0.44, 0.89]) with high heterogeneity (I 2 = 77.9%, p < 0.001) in Fig. 2 . Of which there were 20 trials 14, 25, [27] [28] [29] [30] [32] [33] [34] [36] [37] [38] [39] [40] [41] [42] [43] [44] that assessed the effect of CHM on the cognition compared with Donepezil (SMD = 0.65, 95% CI [0.41, 0.89], I 2 = 79.1%, p < 0.001). One study evaluated the effect of CHM on the cognition compared with Nimodipine and Sanlexi respectively but there were no statistically significant differences between CHM and Nimodipine and Sanlexi.
ADL
A total of 16 studies [15] [16] [17] 25, 27, [29] [30] [31] [32] [33] [34] [37] [38] [39] [40] [41] 26 Danggui shaoyaosan Chinese angelica 6 g, Ligusticum wallichii 6 g, Herbaceous peony 9 g, Atractylodes 9 g, Poria cocos 9 g, Rhizoma alismatis 10 g Jia (2018) 27 Rehmanniae 
Publication bias
The result of Egger's test represented no statistically significant publication bias (p = 0.31). In terms of ADL performance, the result of Egger's test revealed no statistically significant publication bias (p = 0.64).
Discussion
We conducted a systematic review and meta-analysis to evaluate the efficacy of CHM on cognition and ADL in patients with AD. Our findings indicated that the CHM may enhance the cognitive function and ADL compared with conventional drug therapy, at least as effective as other drugs. However, overall risk of bias prevents the firm conclusion. The results need to be interpreted with caution, especially for practitioners who recommend prescriptions to patients.
Pooled analysis indicated that after taking CHM, AD patients can improve their abilities in terms of cognition and activity with significant effect. Although several studies failed to show the superior effects of CHM on cognitive function and ADL compared with conventional drugs, these results may be interpreted as the equivalent effects of CHM with conventional drug therapies. 15, 17, 20, 36, 46 In the Chinese medical theories, the multi-herbs of CHM may have synergetic effects on to regulate the Amyloid beta and calcium disorder, as accumulating Amyloid beta and calcium disorder are associated with the physiology pathology of AD. [47] [48] [49] For example, CHM (i.e., Yizhi formula) can reduce the A␤ aggregation and calcium ion activity, and further improve the memory abilities in A␤-induced mice. 50, 51 Not only CHM regulated immune-neuroendocrine functions and hemorrheology, but also altered cognitive dysfunction. 52 Taken together, the CHMs seem to have great benefits to the relief of patients with AD though changing or regulating signaling pathways (e.g., calcium, enzyme), neuroregeneration, and even reducing A␤ concentration. 53, 54 Note:"+" low risk of bias; "?" unclear risk of bias; "−" high risk of bias. We would like to acknowledge several limitations in this current review study. First, although the present systematic review and meta-analysis was not registered in PROSPERO, we tried to avoid the bias in the post hoc analysis. Second, there are several intrinsic caveats in the primary studies and they may affect the quality of this study. Third, original authors did use proper sample size calculation, and this may underestimate the efficacy of intervention. Fourth, we did not perform meta-regression to find the cause of heterogeneities and this may exaggerate the effects of the treatment. Finally the prescription and doses of CHMs were vary according to the studies and these may occur the heterogeneity of meta-analysis. In conclusion, the results of this systematic review suggest that CHM treatment may have potential effects on improving cognitive function and ADL for individuals with AD. However, the evidence is limited because of high risk of bias of included studies. Further rigorous studies are needed to confirm the efficacy.
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